BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $80.0 million of shares of its common stock.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announced a proposed underwritten public offering of 10 million American Depositary Shares, each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share.

Quoin Pharmaceuticals Ltd. announced the closing of its previously announced public offering of 11,050,000,000 ordinary shares represented by 2,210,000 American Depositary Shares at a purchase price of $5.00 per ADS and pre-funded warrants to purchase 5,750,000,000 ordinary shares represented by 1,150,000 American Depositary Shares at a per pre-funded warrant price of $4.9999 for an aggregate gross proceeds of $16.8 million.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrade to its full-featured SRT-100 Vision™ system with new state-of-the-art solid state High-Frequency Ultrasound.

Azenta, Inc. reported financial results for the third quarter ended June 30, 2022.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer.

Alcon, the global leader in eye care, reported its financial results for the three and six months ended June 30, 2022.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for the second quarter ended June 30, 2022.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, announced that Aziyo co-founder C. Randal Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.

Catalent, Inc. announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited .